NCT00316641

Brief Summary

The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 21, 2006

Completed
Last Updated

November 7, 2006

Status Verified

March 1, 2006

First QC Date

April 20, 2006

Last Update Submit

November 6, 2006

Conditions

Hyperlipidemia

Interventions

Lipid-lowing TeaDRUG

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC\>=200mg/dL),or TG\>=200mg/dL but \<400mg/dL,or LDL-C\>=130mg/dL)
  • Patient who has signed the informed consent form

You may not qualify if:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT\>2x ULN)
  • Patient with renal insufficiency (serum creatinine\>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University Hospital

Taichung, 404, Taiwan

RECRUITING

MeSH Terms

Conditions

Hyperlipidemias

Condition Hierarchy (Ancestors)

DyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Chia-I Tsai, V.S

    China Medical University Hospital,Taichung,Taiwan

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chia-I Tsai, V.S

CONTACT

886-4-22052121josepho777@yahoo.com.tw

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 20, 2006

First Posted

April 21, 2006

Last Updated

November 7, 2006

Record last verified: 2006-03

Locations

TW(1)